ICAM1 and coronary artery disorder: Furthermore, ICAM-1 showed a clear trend towards an augmented expression in HCAEC treated with sera from CAD patients (1.00 ± 0.06 versus 1.32 ± 0.19, P = 0.07, n = 10, Fig.5C), supporting our hypothesis that miR-222 inhibits ICAM-1 expression (Fig.6).